ACADIA Pharmaceuticals(ACAD) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview - Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID® net product sales guidance to$ 685 to $695 million - Updating DAYBUE ® net product sales guidance to$ 385 to $400 million SAN DIEGO, CA, November 5, 2025 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. "Acad ...